Business
Lakewood-Amedex Biotherapeutics Announces Positive Antimicrobial Resistance Data for Lead Candidate Targeting Infected Diabetic Foot Ulcers
Lakewood-Amedex Biotherapeutics Inc., (NASDAQ: LABT) a clinical-stage biotechnology company advancing a novel class of potent, fast-acting, broad-spectrum antimicrobials for infectious diseases called the Bisphosphocin® class, today announced positive antimicrobial resistance (AMR) data for its lead compound, Nu-3, which is being developed as a topically delivered treatment for infected diabetic foot ulcers (iDFU).
About this update from Lakewood-amedex Biotherapeutics Inc.
[{"type":"text","content":"Nu-3 represents a novel class of potent, fast-acting, broad-spectrum antimicrobials called Bisphosphocins®","length":106,"tagName":"p"},{"type":"text","content":"SARASOTA, Fla., May 1, 2026 /PRNewswire/ -- Lakewood-Amedex Biotherapeutics Inc., (NASDAQ: LABT) a clinical-stage biotechnology company advancing a novel class of potent, fast-acting, broad-spectrum antimicrobials for infectious diseases called the Bisphosphocin® class, today announced positive antimicrobial resistance (AMR) data for its lead compound, Nu-3, which is being developed as a topically delivered treatment for infected diabetic foot ulcers (iDFU).","length":462,"tagName":"p"},{"type":"image","alt":"Lakewood-Amedex Biotherapeutics Inc. (PRNewsfoto/Lakewood-Amedex Biotherapeutics Inc.)","displaySize":"","headline":null,"caption":"Lakewood-Amedex Biotherapeutics Inc. (PRNewsfoto/Lakewood-Amedex Biotherapeutics Inc.)","className":"","disableSlideshowImg":false,"size":{"original":{"width":400,"height":265,"url":"https://media.zenfs.com/en/prnewswire.com/fdc26168a77475cab607f9d367d14d43"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/blfhaGRBqtvusCvNb93wvw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTcwNTtoPTQ2Nw--/https://media.zenfs.com/en/prnewswire.com/fdc26168a77475cab607f9d367d14d43","width":400,"height":265}},"href":"https://mma.prnewswire.com/media/2618352/Lakewood_Amedex_Biotherapeutics_Logo.html","hrefExternal":true,"rel":"nofollow"},{"type":"text","content":"Nu-3 is one of a new class of antimicrobial compounds discovered by Lakewood-Amedex Biotherapeutics called the Bisphosphocin® class, which are also being explored in pre-clinical studies as potential treatments for complicated urinary tract infection (cUTI) and pulmonary infections. The Bisphosphocin® class of compounds have been shown in vitro to rapidly kill bacteria through a pH and concentration dependent destabilization of the bacterial cell membrane, typically achieving this effect in under one minute of exposure. This mechanism of action offers the potential to reduce the threat posed by antibiotic-resistant bacterial strains, including Methicillin-resistant Staphylococcus aureus (MRSA), Vancomycin-resistant Enterococci (VRE), and others.","length":755,"tagName":"p"},{"type":"text","content":"In laboratory studies using a serial passage of E. coli and MRSA in the presence of Nu-3 for 21 days, Nu-3 showed...